Form 4: Xencor Executive Exercises Options and Sells Shares Under 10b5-1 Plan

A Xencor executive, John R. Desjarlais, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• John R. Desjarlais, a Senior Vice President and CSO at Xencor Inc., executed transactions involving company stock.
• On November 11, 2024, Desjarlais exercised options to acquire 68,684 shares at $15.69 per share.
• On the same day, 68,684 shares were sold at a weighted average price of $23.4791, with prices ranging from $23.25 to $24.09.
• These sales were to cover the cost of the options and estimated tax liabilities.
• On November 12, 2024, Desjarlais exercised options to acquire 12,774 shares at $15.69 per share.
• Following these transactions, Desjarlais directly owns 212,878 shares of Xencor stock.

Sentiment

Score: 6

Explanation: The document reflects routine transactions under a pre-arranged plan, which is neither particularly positive nor negative. The sale of shares could be seen as slightly negative, but it's balanced by the option exercises.

Positives

• The executive's transactions are part of a pre-arranged 10b5-1 plan, which is a common practice for insiders to avoid accusations of trading on non-public information.
• The exercise of options indicates the executive's belief in the company's long-term value.

Negatives

• The sale of shares, even if for tax purposes, could be interpreted negatively by some investors as a reduction in the executive's stake.

Risks

• The market may react negatively to the sale of shares by a high-ranking executive, even if it is part of a pre-planned strategy.
• Fluctuations in the stock price could impact the value of the remaining shares held by the executive.

Industry Context

This is a routine filing related to executive compensation and stock transactions, common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to manage insider trading risks.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including biotech firms like Xencor.
• Stock option grants and exercises are standard components of executive compensation packages in the biotechnology industry, similar to companies like Amgen and Regeneron.
• The vesting schedule of the options, with a four-year vesting period, is also typical in the industry.

Stakeholder Impact

• Shareholders may be interested in the executive's transactions as an indicator of management's confidence in the company.
• The transactions have a minor impact on the overall share count.

Key Dates

Keywords

Xencor, Stock Options, Form 4, Insider Trading, 10b5-1 Plan, Executive Compensation, Share Sales